The 1st International Electronic Conference on Pharmaceutics
1–15 Dec 2020
Pharmaceutics, Dosage Form, Formulation, Drug Delivery
- Go to the Sessions
- Event Details
We are pleased to announce that the 1st International Electronic Conference on Pharmaceutics was successfully closed with the high visibility of 7387 views and 5730 unique visitors! Thank you for your active participation in it.
We hope you enjoyed the conference and we would like to take this opportunity to invite you to submit your related work to the joint special issue "Selected Papers from the 1st International Electronic Conference on Pharmaceutics (IECP 2020)".
Welcome from the Chairs
Dear colleagues,
It is our pleasure to invite you to participate in the 1st International Electronic Conference on Pharmaceutics that will be held online at https://sciforum.net/conference/IECP2020 from 1 to 15 December, 2020. Participation in the conference is free.
The drive for new, efficient, and cost-effective drugs and medical products has led to exciting new developments and innovative research in the field of pharmaceutics and pharmaceutical technology in recent years. Significant changes are occurring in drug production and development, such as the movement from batch to continuous manufacturing and to more environmentally sustainable methods for drug manufacturing, the shift to personalized medicine, and the growing importance of in silico methods for drug development.
The 1st International Electronic Conference on Pharmaceutics will bring together experts from academia and industry to share new ideas, technologies, and innovations in the broad areas of pharmaceutical formulation, process development, drug delivery, pharmacokinetics, and biopharmaceutics. The online conference will offer a platform for presenting the latest research and will allow participants to engage in discussions with international colleagues via online question-and-answers sessions and discussion groups. The conference will cover a wide range of topics with specific sessions dedicated to:
- Formulation of poorly soluble drugs
- Cyclodextrins in pharmaceutics
- Electrospun/sprayed drug delivery systems
- Advances in pharmacokinetics and drug metabolism
- Transdermal and topical drug delivery
- Brain drug delivery
- Nanomedicine for cancer
All submitted abstracts will be evaluated by the Scientific Committee. Upon acceptance of their abstract, authors will be asked to contribute accepted papers to the conference proceedings and a slide presentation of their work. The authors of the most outstanding contributions will be invited to submit a full manuscript for potential publication in a Special Issue of the open-access journal Pharmaceutics (Impact Factor: 4.421).
We sincerely hope that you will participate in the 1st International Electronic Conference on Pharmaceutics and look forward to welcoming you online.
IECP 2020 Conference Chairs
Dr. Andrea Erxleben and Prof. Dr. Elisabetta Gavini
Conference Secretariat
Mr. Ryan Pei
Ms. Mia XIONG
Ms. Eve Yang
Email: iecp@mdpi.com
Call for Submissions
The 1st International Electronic Conference on Pharmaceutics will be held online from 1 to 15 December 2020. This event enables the researchers of the science and technology of pharmaceutics and biopharmaceutics to present their research and exchange ideas with their colleagues without the need for travel. All proceedings will be published on the conference homepage in open access format.
Through this event, we aim to cover the following topics:
- Formulation of poorly soluble drugs
- Cyclodextrins in pharmaceutics
- Electrospun/sprayed drug delivery systems
- Advances in pharmacokinetics and drug metabolism
- Transdermal and topical drug delivery
- Brain drug delivery
- Nanomedicine for cancer
The conference will be completely free of charge—both to attend, and for scholars to upload and present their latest work on the conference platform. There will also be the possibility of submitting selected papers to the journal Pharmaceutics with a 20% discount on the APC. This offers you the opportunity to participate in this international, scholarly conference without having the concern or expenditure of travel—all you need is your computer and access to the Internet. We would like to invite you to “attend” this conference and present your latest work.
The Scientific Committee looks forward to receiving contributions in response to this call, and will be glad to provide any further information to interested parties. Questions may be addressed to the Pharmaceutics Editorial Office at iecp@mdpi.com or pharmaceutics@mdpi.com.
Critical Dates
Conference Chairs
School of Chemistry, National University of Ireland, Galway, Ireland
Department of Chemistry and Pharmacy, University of Sassari, via Muroni 23/a, 07100 Sassari, Italy
Conference Committee
UCL School of Pharmacy, University College London, 29 - 39 Brunswick Square, London WC1N 1AX, UK
Department of Urologic Sciences, Faculty of Medicine, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
Drug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø, Universitetsveien 57, 9037 Tromsø, Norway
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK
Department of Immunology and Microbiology, College of Medicine, University of Texas Rio Grade Valley, McAllen, TX 78503, USA
Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy
Dr Sorrenti Milena is Assistant Professor (2005-present) at the Department of Drug Sciences, University of Pavia. Her research interests and expertise are mainly in the field of Physical Pharmacy, with particular interest in the study of the solid state of pharmaceuticals (polymorphs, solvates, co-crystals), cyclodextrins and their complexes, and in the development of technological procedures (nano- and microparticle production) to improve the biopharmaceutical and technological properties of poorly water-soluble drugs. She is author of 64 publications in scientific journals in the fields of Pharmaceutical Chemistry, Pharmaceutical Technology, Physical Pharmacy and Biopharmacy (h-index: 20; citations: 1532, source Scopus).
University of Modena and Reggio Emilia
Session Chairs
Dr. Andrea Erxleben
School of Chemistry, National University of Ireland, Galway, Ireland
Prof. Dr. Elisabetta Gavini
Department of Chemistry and Pharmacy, University of Sassari, via Muroni 23/a, 07100 Sassari, Italy
Dr. Milena Sorrenti
Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy
Dr. Gareth R. Williams
UCL School of Pharmacy, University College London, 29 - 39 Brunswick Square, London WC1N 1AX, UK
Dr. Norbert Radacsi
School of Engineering, Institute for Materials and Processes, The University of Edinburgh, Sanderson Building, King's Buildings, Edinburgh, UK
Prof. Dr. Kishor M. Wasan
Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada
Prof. Dr. Natasa Skalko-Basnet
Drug Transport and Delivery Research Group, Department of Pharmacy, University of Tromsø, Universitetsveien 57, 9037 Tromsø, Norway
Dr. M. Begoña Delgado-Charro
Department of Pharmacy and Pharmacology, University of Bath, Bath BA2 7AY, UK
Dr. Giovanni TOSI
University of Modena and Reggio Emilia
Dr. Murali Mohan Yallapu
Department of Immunology and Microbiology, College of Medicine, University of Texas Rio Grade Valley, McAllen, TX 78503, USA
Invited Speakers
Reseach Chair in Pharmaceutical Design and Drug Delivery Faculty of Health and Medical Sciences, Department of Pharmacy, University of Copenhagen, Universitetsparken 2, 2100 København Ø, Denmark
Trinity College Dublin, University of Dublin, Dublin, Ireland
Department of Pharmacy University of Copenhagen, Denmark
University of Bradford, Faculty of Life Sciences, School of Chemistry and Bioscience
Université Catholique De Louvain
Synthetic Strategies for the Preparation of Multifunctional Cyclodextrin Derivatives
He joined the CycloLab in 2010 as a PhD student. He graduated in Pharmaceutical Chemistry and Technology chemical at the University of Bologna, major in organic chemistry. He made his PhD studies in the frame of the Marie-Curie Initial Training Network project Cyclon and defended his PhD theses at the Eötvös University of Sciences (Budapest). Since January 2013, he has been working in the organic synthesis team at CycloLab and since 2016 he is the head of this laboratory. His research interest is the fluorescent labelling of cyclodextrin derivatives and the development of new cyclodextrin-based derivatives with targeting functions. He is author or co-author of 60 research papers, over 30 conference presentations and 6 patents. The total number of citations of his papers is over 500.
Synthesis of cyclodextrins
Supramolecular chemistry of cyclodextrins and their inclusion complexes containing bioactive guest compounds
Emeritus Professor and Senior Research Scholar in the Department of Chemistry, University of Cape Town (2015-present); Director of the Centre for Supramolecular Chemistry Research (2005-2019); research interests and expertise are in the area of solid-state chemistry of cyclodextrins and their complexes, drug polymorphs and various multi-component systems containing APIs (solvates, co-crystals).
Supramolecular chemistry
Drug delivery: application of Cyclodextrins
Drug delivery: application of Cyclodextrins
Dr. Rita AMBRUS, female is an Associate Professor in Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged. Professor Ambrus is also an experimental leader of Nanotechnological Reserch group of Inderdisciplinary Excellence Centre University of Szeged. Her research interest is development of technological procedures (nano- and microparticle production) and alternative drug administration (pulmonar and intranasal) to reach improved bioavailability of poorly water-soluble drugs. She published more than 120 research article (IF: 239.7; Q1/D1 type of publication: 57; First or corresponding author by 50 publications) with 734 independent citations and her H index is 19. She received Zoltan Magyary National Exellence Scholarship, Janos Bolyai Award of the Hungarian Academy of Sciences, New National Exellence Scholarship, Best supervisor Award of the Year at Faculty of Pharmacy and Best Young Scientis Award of the year at University of Szeged. She has great experience in working in multidisciplinary projects.
Department of Urologic Sciences, Faculty of Medicine, The University of British Columbia, Vancouver, BC V6T 1Z3, Canada
The use of lipid-based drug delivery systems in the development of a novel oral amphotericin B formulation to treat systemic fungal and parasitic infections.
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, H-4032 Debrecen, Hungary
Biological studies on cyclodextrins
Dr. Ferenc Fenyvesi Qualification: Pharmacist (Pharm.D.), 2001, University of Debrecen Scientific degree: 2009 Ph.D., University of Debrecen 2018 Habilitation, University of Debrecen Work experience: 2019- Associate Professor, University of Debrecen, Faculty of Pharmacy, Department of Pharmaceutical Technology Education experience: Graduate Programs: Pharmaceutical Technology and Nanopharmaceutics teaching courses in the Faculty of Pharmacy in Hungarian and English programs. Field of interest: - biological effects of cyclodextrins in vitro and in vivo, - cyclodextrin-cell membrane interactions - cellular internalization of cyclodextrins, - biological barriers - solubility enhancement and drug delivery with cyclodextrins, - interactions of biomolecules with cyclodetxrins
Research interests: drug absorption models; drug absorption enhancement by excipients; preparation and examination of drug-cyclodextrin complexes; cellular effects of cyclodextrins
Centre for Nanofibers and Nanotechnology, Department of Mechanical Engineering, National University of Singapore, Singapore 117575, Singapore
Department of Mechanical Engineering, University College London (UCL), London WC1E 7JE, UK
Advanced Manufacturing Research for Healthcare
Professor Mohan Edirisinghe FREng holds the established Bonfield Chair of Biomaterials in the Department of Mechanical Engineering at University College London (UCL) and has served as a University of London professor for over 20 years. He was appointed to this UCL chair in December 2005 and prior to this he was Professor of Materials at Queen Mary University of London. He has actively pursued advanced materials processing, forming and manufacturing research, for over 25 years publishing over 500 journal papers with a H-index of 63 and over 14000 citations. 24 of his journal papers are cover featured (this includes several in the Journal of The Royal Society Interface) with 16 of these in the last five years. In addition, his research has led to many inventions and patents and he has also delivered over a 100 keynote/invited lectures at many different international conferences and meetings worldwide, particularly in the USA (major recent meetings include: TMS, MS&T and MRS). He has supervised over 250 researchers, graduating over a 100 doctoral students (over 40 to date at UCL), and has been awarded grants to the value of over £25 million, with 43 UK Research Council grants including two Platform Grants which have given him the opportunity to adventurously explore novel avenues of forming and manufacture of advanced materials for application in key areas such as healthcare. His research has won many prizes including the Royal Society Brian Mercer (Innovation) Feasibility Award an unprecedented three times (2005, 2009 and 2013), the 2010 Materials Science Venture Prize and the 2012 Presidents Prize of the UK Biomaterials Society to recognise outstanding contributions to the biomaterials field. In 2017 he was the recipient of The Royal Academy of Engineering Armourers & Brasiers prize for excellence in Materials Engineering and the Premier IOM3 Chapman Medal for his distinguished research in the field of biomedical materials.
Department of Biomedical Engineering, University of Memphis, 330 Engineering Technology Building, Memphis, TN 38152, USA
List of Keynotes & Videos from Invited Speakers
Keynotes
Cyclodextrins as Multipurpose Materials for Bone Regenerationby Carmen Alvarez-Lorenzo
Keynotes
Cyclodextrins in Traditional and Alternative Drug Formulationsby Rita Ambrus
Keynotes
Multi-Component Solid Forms of Organic Compoundsby Tom Leyssens
Keynotes
Advanced Manufacturing Research for Healthcareby Mohan Edirisinghe
Keynotes
Investigating to Optimal Ratio between Drug and co-former in co-amorphous Systemsby Thomas Rades
Keynotes
“New” Solutions to the Problem of Poorly Soluble Drugs – the Role of "Green", anti-Crystal Engineeringby Lidia Tajber
Keynotes
Amorphous Stabilisation using Proteins as Excipients
by Korbinian Löbmann
Keynotes
Supramolecular Chemistry of Cyclodextrins and Their Inclusion Complexes Containing Bioactive Guest Compounds
by Mino Caira
Keynotes
Development of a Novel Oral Amphotericin B Formulation (iCo-019) to Treat Systemic Fungal and Parasitic Infections
by Kishor M. Wasan
Keynotes
Current Progress of Electrospun Nanocarriers for Drug Delivery Applications
by Seeram Ramakrishna and Mina Zare
Keynotes
Electrospun Polydioxanone Templates Loaded with Chloroquine Modulate Template-Induced NET Release and the Inflammatory Response
by Allison E. Fetz, Shannon Wallace and Gary L. Bowlin
Keynotes
Electrospinning of Biomolecules and Cell-derived Bodiesby Gareth R. Williams
Keynotes
Synthetic Strategies for the Preparation of Multifunctional Cyclodextrin Derivatives
by Milo Malanga
Abstract
Cyclodextrins (CDs) are cyclic oligosaccharides able to modify the solubility, stability and the aggregation behaviour of a large variety of molecules via complexation. Thanks to their water solubility and biocompatibility, CDs are particularly well-considered as building-blocks for the construction of nanodevices within the nanomedicine field, such as biomolecular sensors and gene/drug delivery systems. CDs have been widely utilized as pharmaceutical excipients and have been recently rediscovered as API in form of (2-hydroxypropyl)-β-cyclodextrin and Sugammadex.
In order to achieve specific purposes, these versatile sugars can be ad-hoc chemically modified with additional functionalities such as fluorescent moieties, photosensitive groups and units targeting biological systems. However, the controlled and regioselective functionalization is quite often challenging due to the large number of hydroxyl groups present on the macrocycles and the substantial differences in their reactivities according to their position on the ring. Thus, well-defined synthetic pathways must be thoroughly planned for each target derivative and the development of versatile synthetic procedures is highly desirable in this field.
In this contribution, the syntheses and the possible uses of CD-based fluorescent systems in imaging processes will be presented through several examples. In particular, the synthetic approaches towards rhodaminyl, fluoresceinyl, nitrobenzofuranyl and anthracenyl CD-based systems will be described and their applications in the visualization and/or targeting of biological process will be discussed.
The preparation of CD-based architectures combining molecules able to release singlet oxygen (1O2) and nitric oxide (NO) will be disclosed together with their utility in photodynamic therapy (PDT). In particular, the synergistic effect of modified CDs and photosensitizers such as porphyrins, xanthene dyes and trifluoromethyl-nitroanilines will be shown.
Green synthetic methods for the production of active-targeting delivery systems such as folate-appended CDs will be discussed and the manufacture of amphiphilic CDs for the effective stabilization and complexation of DNA and RNA will be elucidated. Finally, the syntheses of the two CD-based APIs, (2-hydroxypropyl)-β-cyclodextrin and Sugammadex will be analysed and examined with particular attention to the industrial scale-up.
Keynotes
Biological Studies on Cyclodextrins
by Ferenc Fenyvesi
Keynotes
Building Up Co-Crystals: Structural Motif Consistencies Across Families of Co-crystals
by Colin Seaton
Instructions for Authors
Submission
Submission should be completed online by authors by registering with https://sciforum.net/ and using the “Start New Submission” function once logged into system.
- Scholars interested in participating in the conference can submit their abstract (about 200–300 words describing the manuscript for Proceedings) online at this website until 1 November 2020.
- Based on the submitted abstract, the Conference Committee will conduct a pre-evaluation of whether a contribution from the authors of the abstract will be welcome for the 1st International Electronic Conference on Pharmaceutics. All authors will be notified by 6 November 2020 about the acceptance of their abstract.
- If the abstract is accepted for this conference, the author will be invited to prepare a full description of their work (max. 8 pages), optionally accompanied by a PowerPoint presentation/poster, until the submission deadline of 20 November 2020.
- The conference proceedings papers and presentations will be available for discussion on https://sciforum.net/conference/IECP2020 during the time of the conference 1–15 December 2020 and will be published in the journal Proceedings.
- The open access journal Pharmaceutics will publish a conference Special Issue, while accepted abstracts will be published in the conference proceedings. After the conference, the Conference Committee will select abstracts for which extended papers may be included for publication in the Special Issue of the journal Pharmaceutics (the submission to the journal is independent from the conference proceedings and will follow the usual process of the journal, including peer review and application of an APC).
Proceedings Manuscripts
Manuscripts for Proceedings must conform to the following structure:
First page:
- Title
- Full author names
- Affiliations (including full postal address) and authors’ email addresses
- Abstract (200–250 words)
- Keywords
- Introduction
- Methods
- Results and Discussion
- Conclusions
- (Acknowledgments)
- References
Manuscripts should be prepared in MS Word or any other word processor and should be converted to PDF format before submission. The publication format will be PDF. The manuscript should count at least 3 pages (incl. figures, tables, and references) .
Microsoft Word
Authors must use the Microsoft Word template to prepare their manuscript. Using the template file will substantially shorten the time to complete copy-editing and publication of accepted manuscripts. Manuscript prepared in MS Word must be converted into a single file before submission. Please do not insert any graphics (schemes, figures, etc.) into a movable frame which can superimpose the text and create difficulties related to layout.
Manuscript Preparation
- Paper Format: A4 paper format, the printing area is 17.5 cm × 26.2 cm. The margins should be 1.75 cm on each side of the paper (top, bottom, and left and right sides).
- Formatting/Style: Papers should be prepared following the style of the IECP2020 template. The full titles and cited papers must be given. Reference numbers should be placed in square brackets [ ], and placed before the punctuation; for example, [4] or [1–3], and all the references should be listed separately as the last section at the end of the manuscript.
- Author List and Affiliation Format: Authors’ full first and last names must be given. Any abbreviated middle names can be added. For papers written by various contributors, a corresponding author must be designated. The PubMed/MEDLINE format is used for affiliations: complete street address information including city, zip code, state/province, country, and email address should be added. All authors who contributed significantly to the manuscript (including writing a section) should be listed on the first page of the manuscript, below the title of the article. Other parties, who provided only minor contributions, should only be listed under Acknowledgments. A minor contribution might be a discussion with the author, reading through the draft of the manuscript, or performing English corrections.
- Figures, Schemes, and Tables: Authors are encouraged to prepare figures and schemes in color. Full color graphics will be published free of charge. Figure and schemes must be numbered (Figure 1, Scheme I, Figure 2, Scheme II, etc.) and an explanatory title must be added. Tables should be inserted into the main text with numbers and titles supplied for all tables. All table columns should have an explanatory heading. Please supply legends for all figures, schemes, and tables. The legends should be prepared as a separate paragraph of the main text and placed in the main text before a table, figure, or scheme.
Presentation Slides
Authors are encouraged to prepare a presentation in PowerPoint or similar software, to be displayed online along with the manuscript. Slides, if available, will be directly displayed on the website using Sciforum.net’s proprietary slides viewer. Slides can be prepared in exactly the same way as for any traditional conference where research results can be presented. Slides should be converted to the PDF format before submission so that our process can easily and automatically convert them for online displaying.
Video Presentations
Authors are also encouraged to submit video presentations. The video should be no longer than 20 minutes and be prepared with the following formats:
- MOV
- MPEG4
- MP4
- AVI
- WMV
- MPEGPS
- FLV
The video should be submitted via email before 16 November 2020.
Presentation of Posters
Posters will be available on this conference website during and after the event. As with papers presented at conferences, participants will be able to ask questions and make comments about the posters. Posters can be presented without an accompanying Proceedings paper will be available online on this website during and after the e-conference. However, they will not be added to the proceedings of the conference.
Potential Conflicts of Interest
It is the authors’ responsibility to identify and declare any personal circumstances or interests that may be perceived as inappropriately influencing the representation or interpretation of clinical research. If there are no conflicts, please state here “The authors declare no conflicts of interest”. This should be conveyed in a separate “Conflicts of Interest” statement preceding the “Acknowledgments” and “References” sections at the end of the manuscript. Financial support for the study must be fully disclosed under the “Acknowledgments” section.
Copyright
MDPI, the publisher of the Sciforum.net platform, is an open access publisher. We believe that authors should retain the copyright to their scholarly works. Hence, by submitting a communications paper to this conference, you retain the copyright of your paper, but you grant MDPI the non-exclusive right to publish this paper online on the Sciforum.net platform. This means you can easily submit your paper to any scientific journal at a later stage and transfer the copyright to its publisher (if required by that publisher).
List of accepted submissions (94)
Id | Title | Authors | Presentation Video | Poster PDF | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
sciforum-038167 | Boosting drug bioavailability in men but not women through the action of an excipient | , , , , , , , | N/A | N/A |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Active pharmaceutical ingredients are routinely formulated with a range of excipients in the manufacture of drug products. Excipients are considered to be inert components of the formulations, although recent research has contested its inactive behaviour. This study investigated the effect of the excipient polyethylene glycol 400 (PEG 400) on the oral bioavailability and intestinal permeability of cimetidine in male and female human volunteers. Aqueous solutions of cimetidine with pharmaceutically relevant concentrations of PEG 400 at 0% (control), 0.3%, 0.5%, 0.7% and 1.0% w/v were orally administered to both sexes. Urine samples were then collected and assayed for the determination of cimetidine which reflected oral bioavailability. This human study showed that PEG 400 at 0.3%, 0.5% and 0.7% w/v concentrations significantly increased cimetidine bioavailability by 34%, 58% and 41% respectively, although this enhancement was only demonstrated in men and not women (p < 0.05). Ussing chamber transport studies with male human jejunal tissues revealed that cimetidine permeability increased by 26%, 48% and 29% with PEG 400 at 0.3% w/v, 0.5% w/v and 0.7% w/v respectively (p < 0.05). No such enhancement was demonstrated in female tissues (p > 0.05). We have shown that PEG 400 interacts with intestinal P-glycoprotein (P-gp) expression differently in males and females. The mechanistic action of PEG 400 at gut level was further investigated on human jejunal tissues following the pre-treatment of the P-gp inhibitor valspodar on the transport of cimetidine. When intestinal P-gp was inhibited, the sex- and dose-dependent modulatory effect of PEG 400 with cimetidine was completely eradicated, thus confirming that PEG 400 has a modulatory – rather than inhibitory – effect on P-gp. In sum, the widely used excipient PEG 400 is not inert at pharmaceutically relevant concentrations and its modulatory effect is demonstrated at a human clinical level. Such pharmacological effects, however, are sex- and dose-dependent via its modulation on intestinal P-gp, as evidenced by the boost in cimetidine bioavailability only in male human volunteers. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-038422 | Title: Oral raft forming in situ gelling system for site specific delivery of calcium | , | N/A | N/A |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Abstract : In situ gelling Raft forming system (GRFS), a novel sol-gel system of calcium carbonate (CC) was developed with the aim to prolong the gastric residence time and thereby the bioavailability. A simple lattice mixture design was adopted to study the effect of formulation composition (% HPMC K100 M and % Xanthan gum), on buoyancy lag times, percent of CC released at 1hr and 6hr. The mathematical models generated by analysis of variance (ANOVA) indicated that the levels of HPMC K100 M and Xanthan gum were found to significantly affect all the three responses. The optimized formulation developed by numerical optimization technique was found to display short buoyancy lag time (10.90 ± 0.56 sec), minimum burst release (20.74 ± 1.08%) in 1h and controlled yet near complete release (87.25±1.81%) in 6h. The experimental data for the optimized formulations was in agreement with that predicted by the mathematical models proving the validity of the models generated. In vivo radiographic studies in rabbits indicated that optimized batch displayed a mean gastric retention time of 5.64 ± 0.43 h that was significantly higher (P < 0.05) compared to the marketed suspension that exhibited a mean gastric retention time of less than one hour. The studies proved that the GRFS gastroretentive systems can be a promising platform to improve bioavailability of nutrients having absorption window in upper gastrointestinal tract. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-038440 | Fabrication of Organogel Based Transdermal Delivery System of Loxoprofen Sodium | , | N/A | N/A |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Joint pain with high prevalence and yet without any specific treatment option is posing a challenge to healthcare professionals day by day. Amongst several treatment options currently utilized for arthritic joint pain are merely giving symptomatic relief rather than curative treatment. Non-steroidal Anti-inflammatory Drugs (NSAIDs) are the most widely accessed treatment option amongst all. But their adverse effects profile is a major hurdle for their use, especially in elderly patients. Present study was focused to develop a transdermal patch of a novel NSAID Loxoprofen sodium with enhanced penetration and improved patient compliance. Pluronic lecithin organogel (PLO) was selected as transdermal drug delivery platform to enhance its penetration through skin. Moreover transdermal route will bypass first pass metabolism, GI side effects and necessity to administer drug through oral route. All of these credentials ultimately improved patient compliance. Several experimental batches (PL1 to PL8) were formulated to prepare PLO of loxoprofen sodium. All the batches were evaluated for physical appearance, pH, viscosity, spreadability, drug content and in vitro drug diffusion profiles. An optimized batch was selected on the basis of obtained results. It showed sustained drug release upto 12 hrs. The study evidenced that similar transdermal formulations of other NSAIDs can significantly enhance current treatment scenario for joint pain. Moreover, conversion of such formulations in transdermal patch or other forms ensure sustained and reproducible transdermal flux which can be further fabricated as bioequivalent to the oral formulations. Further studies can be designed to evaluate the clinical applicability of the formulation. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-038617 | Preparation of Magnetic-Fluorescent Bifunctional Microrods as a Drug Delivery System via One-step Electrospraying | , , | N/A |
Show Abstract |
|||||||||||||||||||||||||||||||||||||
Magnetic-fluorescent bifunctional drug delivery system which possesses magnetic targeting and fluorescent tracing capabilities, effectively improves the delivery efficiency of drugs. With the in-depth study of the properties of non-spherical microparticles, it is found that the shape of the microparticles also plays a key role in drug delivery. Because of the unique shape, rod-like microparticles have exhibited great drug molecule metabolic dynamics and excellent anti-tumor effects during the process of treatment. In this study, Fe3O4/NaYF4: Eu3+/PLGA magnetic-fluorescent bifunctional microrods were prepared via one-step electrospraying. Unlike other methods that require complicated steps or expensive equipment, one-step electrospraying is a facile and low-energy method. The prepared magnetic-fluorescent bifunctional microrods possessed uniform rod-like morphology. Compared with magnetic-fluorescent bifunctional microspheres in same volume, it was found that the microrods showed a lower water contact angle. The results of hysteresis curve and fluorescence spectrum suggested the excellent magnetic and fluorescent properties of magnetic-fluorescent bifunctional microrods. After co-cultured with A549 cells or endothelial cells, the cell viability testing results confirmed the wonderful biocompatibility of microrods. When the drug doxorubicin was loaded by the immersion method, the microrods showed a higher drug entrapment efficiency and drug-loading capacity in comprasion with microspheres. In addition, microrods loaded with the same drug in weight showed stronger cytostatic effects after two days of co-culture with A549 cells. In summary, the magnetic-fluorescent bifunctional microrods prepared via one-step electrospraying will be promising candidates for biomedical applications in drug delivery, targeting and tracking. |
|||||||||||||||||||||||||||||||||||||||||
sciforum-038621 | Effects of Transport Inhibitors on the Internalization of Cellular Vesicles by Different Breast Cancer Cell Lines | , , | N/A | N/A |
Show Abstract |
||||||||||||||||||||||||||||||||||||
Liposomes are spherical vesicles composed of natural or artificial lipids and are used as drug carriers. However, their surface needs modification with ligands to target specific tissues. Cell- derived Vesicles (CVs) are bioinspired drug carriers, as they derive from whole cells by physical methods. One of their most striking characteristics is the ability to preserve the topology and composition of the molecules present in the plasma membrane of the parental cell, enabling in vivo organotropism and specific drug delivery. The aim of this study is the investigation of the mechanisms by which liposomes and autologous CVs are internalized by 3 different breast cancer cell lines. Two of the selected cell lines, 4T1 and MDA-MB-231, are triple negative breast cancer cell lines, and the third one, MCF-7, is negative only for the protein HER2. The elucidation of the mechanism is likely to result to the optimization of specific drug delivery and comprehension of their sub- cellular fate. More specifically, liposomes and CVs were produced, characterized and loaded with the fluorescent dye FITC-dextran. Uptake experiments were performed using inhibitors of the clathrin dependent or caveolin dependent endocytic pathways and after incubating the cells at 4°C, where the active processes are inactivated. The results indicate that the endocytosis of CVs is active, mainly via the caveolin pathway, whereas liposomes are internalized actively by both pathways and also passively, as their uptake at 4°C is not significantly hampered. Acknowledgements: This research has been co‐financed by the European Regional Development Fund of the European Union and Greek national funds through the Operational Program Competitiveness, Entrepreneurship and Innovation, under the call RESEARCH – CREATE - INNOVATE (project code: MIS 5031802). |
List of Authors (331)
Event Awards
To acknowledge the support of the conference esteemed authors and recognize their outstanding scientific accomplishments, we are pleased to launch the Best Presentation Awards and the Best Paper Award. Three winners will be selected and each winner will receive a cash award of 500 CHF and a certificate.
The winners will be announced after the conference.
Terms and Conditions:- Submit full paper with video uploaded after short abstract is accepted
- Originality / Novelty of the paper
- Significance of Content
- Scientific Soundness
- Interest to the readers
- English language and style
The winners will be announce in March 2021.
The Awards
Number of Awards Available: 2
The award will consist of 500 Swiss Francs and a certificate (for two attendees).Number of Awards Available: 1
The award will consist of 500 Swiss Francs and a certificate (for one attendee).Terms and Conditions:
- Submit full paper to the Special Issue
- Originality / Novelty of the paper
- Significance of Content
- Scientific Soundness
- Interest to the readers
- English language and style
Winners Announced Here
Pharmaceutics | IECP 2020 Best Paper Award and Best Presentation Awards—Winners Announced
We are very pleased to announce that the winners of the IECP 2020 Best Paper Award and Best Presentation Awards have been selected by the Conference Committee. Each winner will receive a cash prize of CHF 500 and an award certificate. Please join us in congratulating them!
Best Presentation Awards
- “Supramolecular Chemistry of Cyclodextrins and Their Inclusion Complexes Containing Bioactive Guest Compounds“by Mino R Caira
- “High-Throughput Electrospinning of Bioactive Scaffolds for Bone Regeneration”
by Herman Novik, Marta Clerici, Amir Fahmi, Matej Buzgo and Aiva Simaite
Best Paper Award
- “Analytical Investigation of Cyclodextrin Complexation Using the Co-Grinding Technique in the Case of Terbinafine Hydrochloride”
by Balázs Attila Kondoros, Orsolya Laczkovich, Ottó Berkesi and Zoltán Aigner
We would also like to thank all the authors of published papers for their participation! A high-quality expanded version of your conference paper would be welcome if you would like to submit it to the following Special Issue of Pharmaceutics (Impact Factor 4.421), for which we would be happy to provide a 15% discount (CHF 330) if accepted.
Special Issue: Selected Papers from the First International Electronic Conference on Pharmaceutics (IECP 2020)
Special Issue Website: https://www.mdpi.com/journal/pharmaceutics/special_issues/iecp2020
Submission Deadline: 31 May 2021
Please feel free to let us know if you have any questions. We look forward to hearing from you soon.
IECP 2020 Conference Chairs
Dr. Andrea Erxleben and Prof. Dr. Elisabetta Gavini
Conference Secretariat
Mr. Ryan Pei and Ms. Yvette Wang
Email: iecp@mdpi.com
A. Formulation of Poorly Soluble Drugs
B. Cyclodextrins in Pharmaceutics
Dear Colleagues,
Prof. Elisabetta Gavini and Prof. Milena Sorrenti welcome you to the Cyclodextrins in Pharmaceutics Session of the 1st International Electronic Conference on Pharmaceutics.
First, we would like to thank our invited speakers:
- Professor Carmen Alvaro Lorenzo;
- Professor Rita Ambrus;
- Emeritus Professor Miro Caira;
- Doctor Ferenc Fenyvesi;
- Doctor Milo Malanga.
Their recorded presentations will give an overview of different topics concerning cyclodextrins: from synthesis to supramolecular chemistry, from drug delivery to biological studies.
We also thank the MDPI staff and all the participants.
Thanks to the flexibility of this innovative electronic platform, everyone can access the meeting without further steps and attend the conference completely free of charge.
During the conference period, you will be able to comment on other presentations and otherwise engage with fellow scholars in real time.
In this way, the conference offers a novel opportunity to exchange opinions and views within the scholarly community and to discuss papers and the latest research in a discussion forum.
We hope you enjoy the conference!
Elisabetta Gavini and Milena Sorrenti
Show all published submissions (18) Hide published submissions (18)
Submissions
List of Papers (18) Toggle list
C. Electrospun/Sprayed Drug Delivery Systems
D. Advances in Pharmacokinetics and Drug Metabolism
Show all published submissions (2) Hide published submissions (2)
Submissions
List of Papers (2) Toggle list